Synthesis of Bioinorganic Antimicrobial Peptide Nanoparticles with Potential Therapeutic Properties

Eby, D. Matthew; Farrington, Karen E.; Johnson, Glenn R.

doi:10.1021/bm800512e

Cited by 46 publications

(29 citation statements)

References 70 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1A. 12,28,[30][31][32][33] AMPs have also been attached onto water soluble scaffolds including nanoparticles, 34,35 soluble polymers, 36 micelles, 37-39 hydrogel, 40 and liposomes. Alternatively, the AMPs can be prelocalized on a scaffold or surface before interacting with bacteria as illustrated in Fig.…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial peptide LL-37 on surfaces presenting carboxylate anions

et al. 2015

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs) are part of the immune system in a wide range of organisms. They generally carry positive charges under physiological conditions, allowing them to accumulate on the negatively charged bacterial membrane as the first step of bactericidal action. The concentration range of AMPs necessary for rapid killing of bacteria tested in vitro is much higher than levels found at epithelial surfaces and body fluids in vivo, and close to the a level that is toxic to the host cells. It is likely that AMPs in vivo are localized and act cooperatively to enhance antimicrobial activity, while the global concentration is low thus demonstrating low toxicity to host cells. Herein we employed well-defined mixed self-assembled monolayers (SAMs) to localize LL-37, one of the most studied AMPs, via electrostatic interactions. We systematically varied the surface density of LL-37, and found that the immobilized AMPs not only attracted bacteria Pseudomonas aeruginosa to the surface, but also killed nearly all bacteria when above a threshold density. More significantly, the AMPs displayed low toxicity to human corneal epithelial cells. The results indicated that localization of AMPs on suitable polyanion substrates facilitated the bactericidal activity while minimizing the cytotoxicity of AMPs.

show abstract

Section: Introductionmentioning

confidence: 99%

Antimicrobial peptide LL-37 on surfaces presenting carboxylate anions

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The antimicrobial properties are generally based on the cationic and hydrophobic nature of CAPs, which can physically damage negatively charged microbial membranes. Although hundreds of CAP sequences have been identified, their antimicrobial application is limited by the inherent drawbacks of cationic peptides, including cytotoxicity (e.g., hemolysis), enzymatic instability, and immune surveillance [74]. Delivery strategies such as loading CAPs on silica or paramagnetic nanoparticles have thus been proposed to protect the peptides from proteolytic degradation and immune recognition [74,75].…”

Section: Nanotechnologies In Antimicrobial Treatmentmentioning

confidence: 99%

Nanomedicine in the management of microbial infection – Overview and perspectives

et al. 2014

View full text Add to dashboard Cite

For more than 2 billion years, microbes have reigned on our planet, evolving or outlasting many obstacles they have encountered. In the 20th century, this trend took a dramatic turn with the introduction of antibiotics and vaccines. Nevertheless, since then, microbes have progressively eroded the effectiveness of previously successful antibiotics by developing resistance, and many infections have eluded conventional vaccine design approaches. Moreover, the emergence of resistant and more virulent strains of bacteria has outpaced the development of new antibiotics over the last few decades. These trends have had major economic and health impacts at all levels of the socioeconomic spectrum – we need breakthrough innovations that could effectively manage microbial infections and deliver solutions that stand the test of time. The application of nanotechnologies to medicine, or nanomedicine, which has already demonstrated its tremendous impact on the pharmaceutical and biotechnology industries, is rapidly becoming a major driving force behind ongoing changes in the antimicrobial field. Here we provide an overview on the current progress of nanomedicine in the management of microbial infection, including diagnosis, antimicrobial therapy, drug delivery, medical devices, and vaccines, as well as perspectives on the opportunities and challenges in antimicrobial nanomedicine.

show abstract

“…Eby et al used the cationic decapeptide KSL as a model template molecule and demonstrated that the peptide catalyses self-immobilisation within inorganic matrices [81]. They showed that the resultant AMP nanoparticles retain biocidal activity, protect the peptide from proteolytic degradation, and facilitate its continuous release over time.…”

Section: Challenges To the In Vivo Use Of Antimicrobial Peptidesmentioning

confidence: 99%